NasdaqGM:SPRYBiotechs
ARS Pharmaceuticals (SPRY): Assessing Valuation After European Patent Win Secures Neffy Exclusivity Through 2039
ARS Pharmaceuticals (SPRY) just received a boost as the European Patent Office confirmed all claims in its key neffy nasal spray patent. This strengthens its exclusive rights in over 30 European countries through at least 2039.
See our latest analysis for ARS Pharmaceuticals.
ARS’s confirmed European patent adds to a string of encouraging developments this year, such as its $250 million loan deal and steady progress in neffy’s U.S. launch. Even so, the 1-year total shareholder return is down...